The White House Office of Management and Budget (OMB) removed public comments from the federal regulations website after those comments referenced the cystic fibrosis diagnosis of OMB Director Russell Vought’s daughter, according to reporting in STAT. The removal occurred after at least one commenter described personal benefits from research-funded treatments and raised concerns about the potential impact of a proposed rule on federally funded science.
Magdeleine Bradford-Butcher told STAT that prenatal testing showed her baby had cystic fibrosis. Her clinicians placed her on Trikafta, a therapy described in the article as relatively new and aimed at preventing severe complications from the genetic disease after birth. Bradford-Butcher recounted being told after delivery that, because of recent therapeutic advances, her daughter “has a very good chance of outliving you,” a remark she said she treasured. Bradford-Butcher later submitted a public comment on a pending White House regulation because she feared the proposed changes could jeopardize federal research funding and specific studies.
With encouragement from the Cystic Fibrosis Foundation and a science influencer, Bradford-Butcher submitted a comment to the federal rulemaking docket at regulations.gov describing how research funding had benefited her family and expressing worry about an ongoing study tracking outcomes of children exposed to Trikafta in utero. Shortly after her comment was posted publicly, the STAT report says the comment was taken down by OMB without explanation. The article characterizes that sequence — posting followed by unexplained removal by OMB — as unusual but does not include an OMB statement explaining the removal in the publicly accessible portion of the report.
STAT reports that legal experts described the removal of the comments as unusual. The article frames the experts’ reaction in the context of concerns about transparency in rulemaking and the proper handling of public comments submitted to federal dockets. The publicly available portion of the article does not reproduce detailed legal analysis or cite specific statutes or precedents; it notes only that experts found the removal notable and raised questions about how such actions might affect public participation in administrative processes.
STAT labels the piece a STAT+ exclusive and indicates that part of the article is behind the outlet’s subscriber paywall. The accessible content reports the core events — the personal account, the posting to regulations.gov, and the subsequent removal by OMB — and identifies the author (Anil Oza) and the publication date (Aug. 25, 2026). The article does not provide, in the public portion, further documentation of the removed comment, a direct response from OMB explaining why it removed the entry, or a full transcript of any legal commentary. Those additional details, if any, were not reported in the freely available text.
Bradford-Butcher’s stated concern was that the proposed regulation, described in the article as a pending White House rule that could open federal science funding to more political intervention, might disrupt grants and contracts underpinning clinical studies. She specifically worried that a study following outcomes of children exposed to Trikafta in utero could be cut “for any arbitrary reason,” and that revocation of grants could threaten broader research into pediatric diseases. The removal of comments that reference personal or sensitive medical information—especially when those comments relate directly to why a rule matters to affected individuals—raises procedural and transparency questions about the public rulemaking process, as reported.
The reporter is Anil Oza, identified as a general assignment reporter at STAT focusing on the NIH and health equity. The story was published Aug. 25, 2026, and is presented as a STAT+ exclusive. The accessible portion of the source provides the anecdotes and sequence of events but does not include OMB’s explanation for the removals, full legal analysis, or subsequent developments; the STAT piece indicates that additional coverage and details are available only to subscribers. No other institutions, documents, or outcomes beyond those described above were reported in the publicly available text.